deltatrials
Recruiting PHASE1 NCT05818683

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Sponsor: Janssen Research & Development, LLC

Conditions Metastatic Castration-resistant Prostate Neoplasms Metastatic Hormone-sensitive Prostate Cancer
Interventions Abiraterone acetate plus prednisone (AAP) Apalutamide Cabazitaxel Cetrelimab Darolutamide Docetaxel Enzalutamide JNJ-78278343
Updated 31 times since 2023 Last updated: Feb 12, 2026 Started: Apr 26, 2023 Primary completion: Jun 30, 2026 Completion: Sep 1, 2027

This PHASE1 trial investigates Metastatic Castration-resistant Prostate Neoplasms and Metastatic Hormone-sensitive Prostate Cancer and is currently actively recruiting participants. Janssen Research & Development, LLC leads this study, which shows 31 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

31 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE1

  2. Jan 2026 — Feb 2026 [monthly]

    Recruiting PHASE1

  3. Dec 2025 — Jan 2026 [monthly]

    Recruiting PHASE1

  4. Nov 2025 — Dec 2025 [monthly]

    Recruiting PHASE1

  5. Oct 2025 — Nov 2025 [monthly]

    Recruiting PHASE1

▶ Show 26 earlier versions

  1. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE1

  2. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE1

  3. Jul 2025 — Aug 2025 [monthly]

    Recruiting PHASE1

  4. Jun 2025 — Jul 2025 [monthly]

    Recruiting PHASE1

  5. May 2025 — Jun 2025 [monthly]

    Recruiting PHASE1

  6. Mar 2025 — May 2025 [monthly]

    Recruiting PHASE1

  7. Feb 2025 — Mar 2025 [monthly]

    Recruiting PHASE1

  8. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE1

  9. Nov 2024 — Jan 2025 [monthly]

    Recruiting PHASE1

  10. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE1

  11. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1

  12. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  13. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1

  14. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  15. Apr 2024 — Jun 2024 [monthly]

    Recruiting PHASE1

  16. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE1

  17. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE1

  18. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE1

  19. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE1

  20. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE1

  21. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1

  22. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1

  23. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE1

  24. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE1

  25. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  26. May 2023 — Jun 2023 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Apr 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Research & Development, LLC
Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain, Brooklyn, United States, Grand Rapids, United States, Kurralta Park, Australia, Macquarie University, Australia, Madrid, Spain, Melbourne, Australia, Mineola, United States, New York, United States, Philadelphia, United States and 3 more location s